Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone microarchitecture changes in rheumatoid arthritis patients under anti-TNF therapy
2008-006256-22Phase 4Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Oct 2008
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of infliximab, adalimumab and etanercept in rheumatoid arthritis (RA) (3 arms), sponsored by CHU Saint-Etienne. Primary endpoint: Trabecular volume (bone volume/tissue volume) %. Started Oct 2008; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-006256-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006256-22.